vs
Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($749.2M vs $708.5M, roughly 1.1× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 3.6%, a 15.4% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs 32.0%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs 17.7%).
Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
CLOV vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $749.2M | $708.5M |
| Net Profit | $27.3M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 3.6% | 21.6% |
| Net Margin | 3.6% | 19.1% |
| Revenue YoY | 62.0% | 32.0% |
| Net Profit YoY | — | 15.5% |
| EPS (diluted) | $0.05 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $749.2M | — | ||
| Q4 25 | $487.7M | $708.5M | ||
| Q3 25 | $496.6M | $659.9M | ||
| Q2 25 | $477.6M | $603.3M | ||
| Q1 25 | $462.3M | $558.6M | ||
| Q4 24 | $337.0M | $536.6M | ||
| Q3 24 | $331.0M | $533.3M | ||
| Q2 24 | $356.3M | $528.1M |
| Q1 26 | $27.3M | — | ||
| Q4 25 | $-49.3M | $135.1M | ||
| Q3 25 | $-24.4M | $111.1M | ||
| Q2 25 | $-10.6M | $90.3M | ||
| Q1 25 | $-1.3M | $114.6M | ||
| Q4 24 | $-22.1M | $117.0M | ||
| Q3 24 | $-9.2M | $96.4M | ||
| Q2 24 | $7.4M | $88.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.5% | — | ||
| Q2 24 | 30.3% | — |
| Q1 26 | 3.6% | — | ||
| Q4 25 | -10.1% | 21.6% | ||
| Q3 25 | -4.9% | 21.5% | ||
| Q2 25 | -2.2% | 20.9% | ||
| Q1 25 | -0.3% | 20.3% | ||
| Q4 24 | -6.4% | 23.4% | ||
| Q3 24 | -2.7% | 21.1% | ||
| Q2 24 | 2.0% | 19.9% |
| Q1 26 | 3.6% | — | ||
| Q4 25 | -10.1% | 19.1% | ||
| Q3 25 | -4.9% | 16.8% | ||
| Q2 25 | -2.2% | 15.0% | ||
| Q1 25 | -0.3% | 20.5% | ||
| Q4 24 | -6.6% | 21.8% | ||
| Q3 24 | -2.8% | 18.1% | ||
| Q2 24 | 2.1% | 16.7% |
| Q1 26 | $0.05 | — | ||
| Q4 25 | — | $4.65 | ||
| Q3 25 | — | $3.86 | ||
| Q2 25 | — | $3.10 | ||
| Q1 25 | — | $3.67 | ||
| Q4 24 | — | $3.67 | ||
| Q3 24 | — | $3.01 | ||
| Q2 24 | — | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.6M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $339.4M | $459.1M |
| Total Assets | $697.7M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $177.6M | — | ||
| Q4 25 | $78.3M | $497.0M | ||
| Q3 25 | — | $285.4M | ||
| Q2 25 | — | $46.3M | ||
| Q1 25 | — | $441.4M | ||
| Q4 24 | $194.5M | $669.4M | ||
| Q3 24 | $288.0M | $656.9M | ||
| Q2 24 | $254.8M | $510.9M |
| Q1 26 | $339.4M | — | ||
| Q4 25 | $308.7M | $459.1M | ||
| Q3 25 | $340.9M | $293.6M | ||
| Q2 25 | $344.2M | $172.4M | ||
| Q1 25 | $336.1M | $593.6M | ||
| Q4 24 | $341.1M | $825.5M | ||
| Q3 24 | $342.2M | $881.4M | ||
| Q2 24 | $324.9M | $763.6M |
| Q1 26 | $697.7M | — | ||
| Q4 25 | $541.0M | $2.0B | ||
| Q3 25 | $559.7M | $1.8B | ||
| Q2 25 | $575.0M | $1.6B | ||
| Q1 25 | $583.7M | $1.9B | ||
| Q4 24 | $580.7M | $2.1B | ||
| Q3 24 | $653.0M | $2.1B | ||
| Q2 24 | $674.2M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-66.9M | $192.7M | ||
| Q3 25 | $12.1M | $246.2M | ||
| Q2 25 | $5.4M | $148.5M | ||
| Q1 25 | $-16.3M | $125.8M | ||
| Q4 24 | $34.8M | $190.7M | ||
| Q3 24 | $50.0M | $149.1M | ||
| Q2 24 | $44.8M | $116.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-69.0M | $188.1M | ||
| Q3 25 | $11.4M | $235.5M | ||
| Q2 25 | $4.8M | $142.4M | ||
| Q1 25 | $-16.5M | $115.8M | ||
| Q4 24 | $33.3M | $183.0M | ||
| Q3 24 | $49.6M | $138.5M | ||
| Q2 24 | $44.4M | $103.5M |
| Q1 26 | — | — | ||
| Q4 25 | -14.1% | 26.6% | ||
| Q3 25 | 2.3% | 35.7% | ||
| Q2 25 | 1.0% | 23.6% | ||
| Q1 25 | -3.6% | 20.7% | ||
| Q4 24 | 9.9% | 34.1% | ||
| Q3 24 | 15.0% | 26.0% | ||
| Q2 24 | 12.5% | 19.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 0.6% | ||
| Q3 25 | 0.1% | 1.6% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 0.0% | 1.8% | ||
| Q4 24 | 0.5% | 1.4% | ||
| Q3 24 | 0.1% | 2.0% | ||
| Q2 24 | 0.1% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | 6.04× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLOV
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
